Friday, February 12, 2016
Frenova Renal Research, a drug and medical device contract clinical development services provider dedicated exclusively to renal research, has launched F1RST Up (Frenova Rapid STart Up), an exclusive alliance with recognized leading physician investigators in the nephrology research community.
AstraZeneca and its global biologics research and development arm MedImmune have entered into a collaboration with the University of Michigan and Eli Lilly to identify new therapeutic targets for the treatment of chronic kidney diseases (CKD). The RPC2 consortium (renal precompetitive consortium) will combine extensive clinical and molecular data collected by Professor Matthias Kretzler at the University of Michigan with the R&D expertise of the pharmaceutical industry.
St. Jude Children’s Research Hospital has appointed a financial expert with more than 30 years of experience as the institution’s chief financial officer. Pat Keel will lead the hospital’s financial strategy and management as St. Jude embarks on a $7 billion, six-year plan for conquering cancer and other childhood diseases.
Biogen has joined the Center for Therapeutic Target Validation (CTTV), a public-private collaboration to improve the success rate for discovering new medicines. Originally formed by GlaxoSmithKline, the Wellcome Trust Sanger Institute and the European Bioinformatics Institute (EMBL-EBI), the CTTV fosters deep, ongoing interactions between academic and industry members for the purpose of developing open, transformative approaches to selecting and validating novel targets in drug development.